Anti-VEGF Innovations in Retinal Disease
Emerging anti-VEGF agents offer enhanced durability and anatomic outcomes in retinal disease.
A recent Ophthalmology Times Case-Based Roundtable discussed the structural differences among newer second-generation anti-VEGF agents and their implications for clinical efficacy and treatment durability.
Key Takeaways
Stewart, MD, summarized the key takeaways from the discussion, highlighting real-world experiences and evidence regarding extended treatment intervals and sustained disease control with newer therapies.
Case Study
Stewart described an 83-year-old woman with diabetic macular edema (DME) who had undergone temporal grid laser photocoagulation for macular edema and received bevacizumab (Avastin; Genentech, Inc) intravitreal injections every 4 to 6 weeks.
Stewart is a professor and the chairman emeritus of ophthalmology at Mayo Clinic in Jacksonville, Florida, and the Knights Templar Eye Foundation Inc. Professor in Ophthalmology Research.
Author's summary: Anti-VEGF agents improve retinal disease treatment.
More News
- Chipotle’s Stock Plunges 18% On Lowered Guidance
- The Tech Symphony: AI's Crescendo and the Gadget Orchestra
- Eala falls to Mboko to exit Hong Kong Open
- Letters | Fractured leadership - Navajo Times
- Aspiring Teacher, Student Leader, Lacrosse Standout, Tess Brown ’26 Selected to Attend NCAA Program
- Animal Crossing: New Horizons Gets a Free Update and Switch 2 Edition
- NewJeans loses Ador court battle to leave agency
- Animal Crossing: New Horizons Getting Switch 2 Edition and Free Content Update
- New SMA and RP-SMA FT connectors provide fast and easy assembly
- We need a new Turing test to assess AI’s real-world knowledge